Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Abierto

2 2.04

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.95

Máximo

2.04

Métricas clave
By Trading Economics
Ingresos	663K -7M
Ventas	426K 2.6M
P/B Media del Sector	5.308 48.735
BPA	-0.07
Margen de beneficios	-269.254
Empleados	75
EBITDA	665K -7M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+127.27% upside

Dividendos
By Acuity
Próximas Ganancias	9 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-29M 196M
Apertura anterior	-0.04
Cierre anterior	2

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 oct 2026, 23:56 UTC

Aquestive Therapeutics Inc shares advanced in after-market trading, maintaining a position significantly above Tuesday's close despite a slight retracement.

13 oct 2026, 23:56 UTC

Permian Resources Corp shares are trading lower in after-market hours, slightly improved from earlier lows but still negative, remaining above the 20-day moving average.

13 oct 2026, 23:56 UTC

Emerson Electric Co's shares advanced modestly higher in after-market hours on Tuesday, continuing an upward trend after finishing higher in the last four sessions.

13 oct 2026, 23:56 UTC

Correlated Moves

Comstock Resources Inc shares declined in after-market trading, continuing a downward trend that began after Tuesday's close, amid unusual weakness in activity.

13 oct 2026, 23:56 UTC

Gray Media Inc shares are trading modestly higher in after-market hours following fluctuations since Tuesday's close, currently positioned below the 20-day moving average.

13 oct 2026, 23:56 UTC

The NZD/JPY is trading modestly higher, following fluctuations and a notable peak earlier in the session, amid mixed market conditions.

13 oct 2026, 23:56 UTC

Event

Kura Oncology plans a webcast today with Caspian Therapeutics to discuss KO-7246's development strategy and findings from the EASD Annual Meeting.

13 oct 2026, 23:56 UTC

Carrier Global Corp shares are trading modestly lower in after-market hours, continuing a trend of declining daily closes over the past four sessions.

13 oct 2026, 23:56 UTC

Correlated Moves

Ameren Corp is roughly flat in after-market trading, moving in sympathy with ONE Gas Inc, which is slightly lower amid recent weakness.

13 oct 2026, 23:56 UTC

Matson Inc is trading lower in after-market hours.

13 oct 2026, 23:56 UTC

GBP/JPY is trading slightly higher, maintaining a position near the upper end of its one-month range, amid better-than-expected U.S. existing home sales data.

13 oct 2026, 23:56 UTC

AbbVie Inc saw a modest uptick in after-market trading, gaining ground since Tuesday's close, supported by a generally positive backdrop for the biotechnology sector.

13 oct 2026, 23:56 UTC

FedEx Corp shares are trading modestly lower in after-market hours, continuing a downward trend and nearing the lower end of its one-month trading range.

13 oct 2026, 23:52 UTC

Singapore's Q3 2026 GDP Growth Rate Expected at 1.2% Amid Cautious Market Sentiment and Global Economic Influences

13 oct 2026, 23:52 UTC

US Industrial Production MoM data for September 2026 set to release on October 16, with a modest increase of 0.4% anticipated amid cautious investor sentiment influenced by inflation and Fed interest rate policies.

13 oct 2026, 23:52 UTC

Macro News

The USD/JPY is trading lower as the Japanese yen strengthens against major currencies amid comments from Bank of Japan Governor Kazuho Ueda on potential rate hikes.

13 oct 2026, 23:52 UTC

Japan's upcoming export data release on October 20, 2026, faces cautious market expectations amid mixed economic indicators and declining producer prices.

13 oct 2026, 23:52 UTC

Japan's Upcoming Balance of Trade Data Sparks Caution Amid Persistent Deficits and Rising Import Costs

13 oct 2026, 23:51 UTC

Dollar General Corp shares are trading modestly lower in after-market hours, reaching their lowest cumulative return since Tuesday's close amid notable volatility.

13 oct 2026, 23:51 UTC

Levi Strauss & Co shares are trading modestly lower in after-market hours, retracing to their lowest point of the day after briefly rising above Tuesday's close.

13 oct 2026, 23:51 UTC

News

Etsy Inc shares are trading lower in after-market hours despite Payoneer's renewal of its partnership through 2029 to support international sellers.

13 oct 2026, 23:51 UTC

Expeditors International shares are trading roughly flat in after-market hours, remaining near unchanged following Tuesday's close amid modest fluctuations.

13 oct 2026, 23:51 UTC

Wynn Resorts Ltd. shares declined modestly in after-market hours, finishing at the lowest point of the session and continuing to trade below its 20-day moving average.

13 oct 2026, 23:51 UTC

Match Group Inc. has seen a modest increase in after-market trading, continuing its upward trend since Tuesday's close, remaining above its 20-day moving average.

13 oct 2026, 23:51 UTC

Bank OZK shares are trading lower in after-market hours, continuing a cumulative decline since Tuesday's close and remaining near the lower end of their one-month range.

13 oct 2026, 23:51 UTC

Bath & Body Works Inc shares declined in after-market trading, continuing a downward trend since Tuesday's close, despite peaking earlier in the session.

13 oct 2026, 23:51 UTC

News

DraftKings Inc shares are trading lower in after-market hours as the FTC launches a preliminary inquiry into potential deceptive practices in the sports betting industry.

13 oct 2026, 23:51 UTC

HCA Healthcare Inc shares declined in after-market trading, moving lower from a flat position after Tuesday's close.

13 oct 2026, 23:51 UTC

JD.com Inc shares advanced modestly in after-market trading, peaking shortly after Tuesday's close and remaining near the upper end of their one-month range.

13 oct 2026, 23:51 UTC

PDD Holdings Inc. has gained in after-market trading, reaching a peak return since Tuesday's close and remaining above its 20-day moving average.

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

127.27% repunte

Estimación a 12 Meses

Media 4.5 USD 127.27%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.